Changes in Indications and Oncological Outcomes of Radical Prostatectomy After 2000—Data From 1268 Japanese Patients Treated with Radical Prostatectomy Between 2000 and 2009
Koji Mitsuzuka(Pacific Northwest Diabetes Research Institute), Yoichi Arai(Japan Atomic Energy Agency), Norihiko Tsuchiya(Yamagata University), Yasuhiro Kaiho(Tohoku University), Shintaro Narita(Akita University), Takuya Koie(Hirosaki University), Narihiko Kakoi(Miyagi Prefectural Hospital Organization), Takuhiro Yamaguchi(Tohoku University), Chikara Οhyama(Hirosaki University), Tohru Yoneyama(Hirosaki University), Tomonori Habuchi(Akita University), Tatsuo Tochigi(Miyagi Prefectural Hospital Organization), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization)
Cited by 7
Related Papers
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial
|Journal of Clinical Oncology|2013|253